People · Operator
Named in public records as an officer, director or promoter · active 2012–2017 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| X4 Pharmaceuticals, Inc. | — | Pharmaceuticals | Series B | $73.2M | $1.2B | 2017 |
| Igenica Inc | — | Pharmaceuticals | Series B | $70.0M | $76.5M | 2012 |
John Celebi at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside John Celebi on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Carl Gordon | 1 | 24 |
| Isaac Blech | 1 | 14 |
| David Goeddel | 1 | 10 |
| Michael Gilman | 1 | 6 |
| Michael Wyzga | 1 | 5 |
| Alison Lawton | 1 | 3 |
| Adam Mostafa | 1 | 3 |
| John Diekman | 1 | 3 |
| Alan Walts | 1 | 3 |
| Paula Ragan | 1 | 3 |
| Alan E. Walts | 1 | 3 |
| Gwen A. Fyfe | 1 | 2 |
| Mary Haak-Frendscho | 1 | 2 |
| Mark Goldsmith | 1 | 2 |
| Nancy Lurker | 1 | 2 |
| John Cheney | 1 | 1 |
| Guoqing Chen | 1 | 1 |
| Mike Rothe | 1 | 1 |
| Gwen Fyfe | 1 | 1 |
| Robert Schreiber | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.